Fitness Trends Recombinant Therapeutic Antibodies and Proteins Ma

Recombinant Therapeutic Antibodies and Proteins
Market - Size, Share, trends, and Forecast to 2026
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-
covalent binders. These proteins are highly effective and serve as modernized treatment for rare
as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by
supporting a specifically targeted therapeutic process by compensating the deficiency of an
essential protein. Recombinant proteins have gained significant traction for therapeutic
applications and the number of proteins either launched or approved into clinical trials has
continually increased over the past two decades. According to the National Center for
Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA)
approved over 140 recombinant therapeutic proteins for human use and several hundred are
currently in development. Majority of these proteins are recombinant monoclonal antibodies.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1981
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2
billion in 2017, and is expected to witness a robust CAGR of 12.2% over the forecast period
(2018 – 2026).
Market Dynamics
Recombinant therapeutic proteins and antibodies have gained high traction in clinical
applications. Due to development of antibody-based therapeutics, mammalian expression systems
have experienced a major boost and microbial expression systems continue to be widely used in
industries, which in turn will fuel growth of the market. However, variations in production
methods of therapeutic antibodies can lead to differences in their structure, based on the
selection of recombinant procedure. Most protein therapeutics available in the market are
recombinant and majority of them are in clinical trials for therapy of immune disorders,
cancers, infections, and other diseases. Various engineered proteins, including multi-specific
fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule
drugs, and proteins with optimized pharmacokinetics are under development.